InnoCare Pharma
Beijing, Beijing, China · Biopharma, Biotechnology, Health Care
InnoCare Pharma is a leading biopharmaceutical company that focuses on the treatment of cancer and autoimmune diseases. The company is committed to discovering, developing, and commercializing first-in-class and best-in-class drugs to address unmet medical needs in China and globally. With branches in various cities including Beijing and Hong Kong, InnoCare is actively involved in advancing innova
Key facts
- Headquarters
- Beijing, Beijing, China
- Employees
- 124
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Private
- Website
- innocarepharma.com
- Company page
Recent activity at InnoCare Pharma
- : InnoCare Pharma enters a strategic research collaboration and licensing agreement with Eli Lilly to develop new medicines. (date Fundz recorded it)
- : InnoCare and KeyMed Announce License Agreement with Prolium for ICP-B02 Bispecific Antibody (date Fundz recorded it)
- : InnoCare Pharma and KeyMed Biosciences Announce Exclusive License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Leadership
- Xiangyang Chen, Chief Technology Officer
- Yang Gao, Human Resources Business Partner
- Joey Wu, Associated HR Manager
- Alina Zhang, Head Of Hr
- Ivan Feng, Project Management and Engineering
- Yi Du, InnoCare Pharma Employee
Verified email and direct lines for InnoCare Pharma’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
InnoCare Pharma in the news
- InnoCare Signs Research Deal With Lilly Worth Up to $3.35 Billion - BioPharm International (Sep 24, 2026)
- InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China - Yahoo Finance (Oct 11, 2026)
- InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines - GlobeNewswire (Sep 24, 2026)
- InnoCare Announces First Patient Dosed in Head-to-Head - GlobeNewswire (Nov 08, 2026)
- InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China - GlobeNewswire (Jul 05, 2026)
- InnoCare Announces Orelabrutinib in Combination with - GlobeNewswire (Aug 03, 2026)
- InnoCare Announces Approval of Orelabrutinib in Australia - GlobeNewswire (May 27, 2026)
- Zenas BioPharma and InnoCare Pharma Announce License - GlobeNewswire (Oct 08, 2025)
Companies similar to InnoCare Pharma
- Aquestive Therapeutics, Inc. · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Citius Oncology · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Abivax · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Kairos Pharma Ltd · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
About InnoCare Pharma: questions and answers
What does InnoCare Pharma do?
InnoCare Pharma is a leading biopharmaceutical company that focuses on the treatment of cancer and autoimmune diseases. The company is committed to discovering, developing, and commercializing first-in-class and best-in-class drugs to address unmet medical needs in China and globally. With branches in various cities including Beijing and Hong Kong, InnoCare is actively involved in advancing innova
Where is InnoCare Pharma headquartered?
InnoCare Pharma is headquartered in Beijing, Beijing, China.
How many employees does InnoCare Pharma have?
InnoCare Pharma has about 124 employees.
What is the latest news on InnoCare Pharma?
On Sep 24, 2026, InnoCare Pharma enters a strategic research collaboration and licensing agreement with Eli Lilly to develop new medicines.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy